Table 3.
Characteristics of kidney transplant recipients genotyped (Test cohort n=979) and the rest (non-test cohort). P-value for comparisons between recipients in test versus validation cohort.
| Characteristic | All n= 2,336 | Test Cohort n =979 | Non-Test Cohort n=1,357 | p-value |
|---|---|---|---|---|
| 0.05 | ||||
| Ethnicity: White | 75 % | 77 % | 74 % | |
| Black | 19 % | 17 % | 20 % | |
| Asian | 3 % | 3 % | 3 % | |
| Other | 2 % | 2 % | 3 % | |
| Not Known | <1 % | < 1% | 0 % | |
| Hispanic | 2 % | 2 % | 1 % | 0.99 |
| Male | 63 % | 63 % | 63 % | 0.89 |
| Mean age at enrollment in years | 49 ±14 | 49 ±14 | 49 ±14 | 0.20 |
| Cause of End Stage Kidney Disease: | 0.87 | |||
| Diabetes | 28 % | 31 % | 26 % | |
| Glomerular disease | 21 % | 20 % | 21 % | |
| HTN | 14 % | 12 % | 16 % | |
| Polycystic kidney disease | 13 % | 12 % | 13 % | |
| Other | 21 % | 21 % | 21 % | |
| Unknown | 3 % | 4 % | 3 % | |
| History of diabetes | 36% | 38 % | 35 % | 0.89 |
| Living donor transplant | 58 % | 59 % | 57 % | 0.84 |
| Mean donor age in years | 40 ± 14 | 40 ± 14 | 40 ± 14 | 0.07 |
| Male donor* | 48 % | 46 % | 49 % | 0.12 |
| Cold Ischemia time >24 h* | 8 % | 7 % | 9 % | 0.25 |
| Prior kidney Transplant | 13 % | 14 % | 13 % | 0.63 |
| Need for dialysis in the first 14 days post transplant* | 10% | 8 % | 10 % | 0.005 |
| Final PRA present * | 42% | 35 % | 47 % | <0.001 |
| T or B Crossmatch positive* | 6 % | 5 % | 6 % | 0.92 |
| Plasmapheresis prior to transplants | 3 % | 3% | 2% | 0.35 |
| Zero HLA mismatches | 12 % | 11 % | 12 % | 0.45 |
| Antibody Induction: | <0.0001 | |||
| Monoclonal | 44 % | 40 % | 47 % | |
| None | 4 % | 1 % | 5 % | |
| Other | 3 % | 4 % | 2 % | |
| Polyclonal | 50 % | 54 % | 46 % | |
| Smoking status:* | ||||
| Never | 58 % | 60 % | 57 % | 0.39 |
| Past | 32 % | 31 % | 33 % | |
| Current | 9 % | 9 % | 10 % | |
| Pre-emptive transplant | 29 % | 31 % | 26 % | |
| Steroid withdrawal by day 14 post-transplant | 39 % | 48 % | 30 % | 0.58 |
| Use of Mycophenolate Mofetil | 99% | 99 % | 99 % | |
| CNI type: | 0.03 | |||
| Cyclosporine | 28 % | 22 % | 35 % | 0.90 |
| Tacrolimus | 69 % | 75 % | 62 % | 0.58 |
| None | 3 % | 3 % | 3 % | |
| SPK** | 6 % | 6 % | 5 % | |
| Prior Non-kidney Transplants* | 10 % | 11 % | 9 % | 0.90 |
| CMV Recipient/Donor Status* | 0.88 | |||
| Recipient (−)/Donor (−) | 20 % | 22 % | 19 % | 0.43 |
| Recipient (+) | 63 % | 62 % | 64 % | |
| Recipient (−)/Donor (+) | 17 % | 16 % | 17 % |
Missing data: Living donor gender missing in 7 subjects, need for dialysis in the first 14 days post-transplant missing in 4 subjects, Cold Ischemia time missing in 209 subjects, Final PRA missing in 7 subjects, Plasmapheresis prior to transplant missing in 57 subjects, B/T cell crossmatch missing in 51 subjects, Smoking status missing in 7 subject, Use of Mycophenolate Mofetil and CNI type was missing in 215 subjects, Prior non-kidney transplant missing in 44 subjects, CMV recipient/donor status missing in 44 subjects.
SPK= Simultaneous kidney pancreas transplants